Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505088 | 0.96 | GAA (0.56) | GAATSHRMRGPRX4KDM4ELMNA | |
| SCHEMBL3199685 | 0.88 | GAA (0.55) | GAATSHRMRGPRX4KDM4ELMNA | |
| SCHEMBL11370707 | 0.88 | LMNA (0.49) | GAATSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL19859014 | 0.88 | TSHR (0.47) | GAATSHRMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL1505120 | 0.86 | S1PR4 (0.52) | MRGPRX4KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL12505380 | 0.86 | LMNA (0.48) | GAATSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL20522075 | 0.86 | GAA (0.61) | GAATSHRMRGPRX4LMNAALDH1A1 | |
| SCHEMBL4359950 | 0.85 | TSHR (0.53) | GAATSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL1505156 | 0.85 | GAA (0.57) | GAATSHRMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL1153890 | 0.84 | GAA (0.60) | GAATSHRMRGPRX4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041230-B | NLRP3 inflammation small inhibitor and preparation method and application thereof | 中国海洋大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-116041230-A | NLRP3 inflammation small inhibitor and preparation method and application thereof | 中国海洋大学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | GAA 2290/4885TSHR 598/4885MRGPRX4 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.